Antigen Binding Proteins To Proprotein Convertase Subtilisin Kexin Type 9 (Pcsk9)
Patent No. EP3666797 (titled "Antigen Binding Proteins To Proprotein Convertase Subtilisin Kexin Type 9 (Pcsk9)") was filed by Amgen on Aug 22, 2008. The application was issued on May 17, 2023.
Patent Summary
Monoclonal antibodies that bind to the catalytic domain of PCSK9, a cholesterol-lowering protein, and prevent or reduce the binding of PCSK9 to LDLR. These antibodies can be used to treat or prevent hypercholesterolemia and atherosclerotic diseases by inhibiting PCSK9's function. The antibodies bind to specific regions of PCSK9's heavy and light chain variable domains.
UPC Cases New
Latest UPC cases involving this patent.
Patent Family
Patent Oppositions (3)
Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.
Dossier Documents
The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.
EP3666797
- Application Number
- EP19207796A
- Filing Date
- Aug 22, 2008
- Status
- Granted And Under Opposition
- Apr 14, 2023
- Publication Date
- May 17, 2023
- External Links
- Slate, Register , Google Patents